Free tool
FAERS Monitor: Minivelle
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203752 or its brand name (Minivelle, Estradiol). Reports on generic versions are filed under their own applications.
Reports
49,932
Serious
22,740
46% of reports
Hospitalization
7,279
Death reported
915
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,228
- headache3,036
- nausea2,980
- fatigue2,930
- off label use2,894
- pain2,116
- diarrhoea1,990
- product adhesion issue1,969
- dizziness1,780
- hot flush1,710
- breast cancer female1,709
- arthralgia1,687
- pruritus1,599
- rash1,582
- dyspnoea1,555
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 524 |
| 2005 | 571 |
| 2006 | 402 |
| 2007 | 1,461 |
| 2008 | 428 |
| 2009 | 598 |
| 2010 | 952 |
| 2011 | 840 |
| 2012 | 1,138 |
| 2013 | 1,364 |
| 2014 | 1,835 |
| 2015 | 2,392 |
| 2016 | 2,676 |
| 2017 | 2,464 |
| 2018 | 2,684 |
| 2019 | 3,016 |
| 2020 | 2,958 |
| 2021 | 2,883 |
| 2022 | 3,096 |
| 2023 | 3,581 |
| 2024 | 3,737 |
| 2025 | 5,300 |
| 2026 | 5,031 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,227 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 1,709 | 28.7 | 27.4 | 42,833 |
| product adhesion issueSignal | 1,969 | 24.5 | 23.4 | 42,002 |
| hot flushSignal | 1,710 | 9.8 | 9.3 | 13,171 |
| headacheSignal | 3,036 | 2.0 | 2.0 | 1,661 |
| pruritus | 1,599 | 1.8 | 1.7 | 527 |
| arthralgia | 1,687 | 1.7 | 1.6 | 507 |
| nausea | 2,980 | 1.6 | 1.5 | 671 |
| fatigue | 2,930 | 1.6 | 1.5 | 658 |
| rash | 1,582 | 1.5 | 1.5 | 296 |
| dizziness | 1,780 | 1.5 | 1.4 | 307 |
| pain | 2,116 | 1.5 | 1.4 | 306 |
| off label use | 2,894 | 1.4 | 1.3 | 334 |
| drug ineffective | 4,228 | 1.4 | 1.3 | 413 |
| diarrhoea | 1,990 | 1.3 | 1.2 | 141 |
| dyspnoea | 1,555 | 1.2 | 1.1 | 34 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.